Biosynthetic hyaluronic acid

Hyaluronic acid is a linear glycosaminoglycan: an unbranched chain of alternating N-acetylglucosamine and glucuronic acid, unsulfated and uncomplicated. Its structure is the simplest of any glycosaminoglycan, and almost everything interesting about it follows from length rather than from chemistry.

An unusual enzyme

Most polysaccharides are assembled inside the cell and then exported. Hyaluronan synthase does both at once: it is an integral membrane protein that adds sugars alternately to the growing chain while extruding it through the membrane into the extracellular space.

Two consequences matter. The polymer is made processively, without a template, so its length is not encoded anywhere — it is set by how long the enzyme holds on before releasing, which depends on the enzyme itself and on the supply ratio of the two nucleotide-sugar precursors. And because the chain never accumulates inside the cell, the organism can make enormous quantities of a molecule that would otherwise be osmotically intolerable.

Why it is identical in every species

Hyaluronan has the same structure in humans, in cattle and in the Streptococcus species that make it as a capsule. It carries no species-specific decoration, so it does not present an immunological signature.

For the bacterium this is molecular mimicry — a capsule the host immune system cannot distinguish from its own matrix. For medicine it is the reason hyaluronan is used so freely as a filler, a viscoelastic in eye surgery and a joint injection: the molecule needs no humanisation because there is nothing to humanise.

It is also why the production organism was changed. The natural producers are pathogens that also make streptolysin and other exotoxins, so heterologous expression of the synthase in Bacillus subtilis — a non-pathogen without endotoxin, since it is Gram-positive — separates the molecule from its original organism’s liabilities.

Length is the specification

High-molecular-weight hyaluronan forms entangled, highly hydrated networks and is strongly viscoelastic: shear-thinning under stress and recovering at rest, which is exactly what a joint lubricant or a surgical viscoelastic needs. Low-molecular-weight fragments do not entangle and are watery.

The biology diverges too, and the difference is well documented: high-molecular-weight hyaluronan is broadly anti-inflammatory and space-filling, while short fragments — generated by hyaluronidase or by oxidative damage — act as signals of tissue injury and are pro-inflammatory and pro-angiogenic. The same polymer at different lengths does opposite things. A product specification that states only “hyaluronic acid” therefore says very little; molecular weight and polydispersity are the meaningful figures.

The ceiling is rheological

Because hyaluronan is enormously viscosifying, broth viscosity rises steeply as the product accumulates. Viscous broth mixes poorly and transfers oxygen poorly, so an aerobic culture becomes oxygen-limited by its own product long before nutrients run out.

Titre is therefore capped by rheology, not by metabolism — the pathway could make more, and the vessel cannot supply the oxygen to do it. This is why processes trade molecular weight against yield: conditions that favour longer chains thicken the broth faster and cap titre sooner. Reactor designs with higher torque and unconventional impellers, and fed-batch strategies that manage viscosity over time, are attacking a transport limit rather than a biological one.